RemeGen Reports H1 Net Profit of RMB 4.662 Billion as Licensing Revenue Drives Turnaround
Nashnova编辑部
RemeGen (09995) posted first-half revenue of roughly RMB 5.85 billion, up over fourfold year-on-year, with net profit of RMB 4.66 billion — but the bulk came from a one-off licensing deal, leaving the sustainability question wide open.
Where did the money come from?
Drug sales: Telitacicept (autoimmune) and disitamab vedotin (oncology) both saw strong volume growth, driving a sharp rise in product revenue.
Rights licensing: RemeGen granted AbbVie exclusive rights to develop, manufacture and commercialize pipeline candidate RC148 outside Greater China — a single deal that brought in a massive technology-licensing fee.
This means → the two revenue streams combined produced the 435.74% year-on-year surge; drug sales alone would not come close.
How did the profit margin stretch so wide?
Revenue more than quadrupled, yet R&D spending fell 36% year-on-year to roughly RMB 414 million.
In plain terms = income surged while costs shrank — profit was squeezed out from both ends, amplified by the lump-sum licensing fee on one side and leaner spending on the other.
This reflects a company crossing from a cash-burning R&D phase into early monetization.
Is the turnaround sustainable?
The AbbVie licensing fee is one-off in nature — no comparable windfall is baked into the next reporting period.
This means → strip out the licensing income and the real question is whether Telitacicept and disitamab vedotin can sustain enough sales momentum to keep RemeGen profitable on their own.
In plain terms = the interim report proves RemeGen *can* make money, but not yet that it *will keep* making money — ongoing sales data for the two core drugs is the critical metric to watch.
Content is for reference only, not financial advice.